WallStreetZenWallStreetZen

NASDAQ: DXCM
Dexcom Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DXCM

Based on 17 analysts offering 12 month price targets for Dexcom Inc

Min Forecast
$64.00-22.92%
Avg Forecast
$88.65+6.77%
Max Forecast
$96.00+15.62%

Should I buy or sell DXCM stock?

Based on 17 analysts offering ratings for Dexcom Inc.

Strong Buy
Strong Buy
13 analysts 76.47%
Buy
2 analysts 11.76%
Hold
1 analysts 5.88%
Sell
0 analysts 0%
Strong Sell
1 analysts 5.88%
Our proven Zen Rating quant model "Buy" agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their DXCM stock forecasts and price targets.

DXCM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-04
lockedlocked$00.00+00.00%2026-08-03Find Out Why
lockedlocked$00.00+00.00%2026-07-31Find Out Why
lockedlocked$00.00+00.00%2026-07-31
lockedlocked$00.00+00.00%2026-07-31
JP Morgan
Top 22%
79
HoldMaintains$82.00-1.24%2026-07-31
Piper Sandler
Bottom 4%
4
Strong BuyReiterates$95.00+14.42%2026-07-31
Wells Fargo
Top 14%
87
Strong BuyMaintains$90.00+8.39%2026-07-31
Stifel Nicolaus
Bottom 14%
14
Strong BuyMaintains$95.00+14.42%2026-07-31
Benchmark
Top 28%
73
Strong BuyMaintains$82.00-1.24%2026-07-31

1 of 2

Forecast return on equity

Is DXCM forecast to generate an efficient return?

Company
62.62%
Industry
22.17%
Market
167.94%
DXCM's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DXCM forecast to generate an efficient return on assets?

Company
25.43%
Industry
13.68%
DXCM is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DXCM earnings per share forecast

What is DXCM's earnings per share in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$2.72+5.03%
Avg 2 year Forecast
$3.19+23.1%
Avg 3 year Forecast
$3.80+46.72%
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

DXCM revenue forecast

What is DXCM's revenue in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$5.3B+7.36%
Avg 2 year Forecast
$5.9B+18.99%
Avg 3 year Forecast
$6.6B+32.44%
DXCM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DXCM earnings growth forecast

How is DXCM forecast to perform vs Medical Devices companies and vs the US market?

Company
13.34%
Industry
22.07%
Market
30.83%
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
DXCM's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

DXCM revenue growth forecast

How is DXCM forecast to perform vs Medical Devices companies and vs the US market?

Company
9.71%
Industry
7.3%
Market
13.23%
DXCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DXCM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DXCM vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
DXCM$83.03$88.65+6.77%Strong Buy
PHG$24.59N/AN/AHold
STE$210.76$271.33+28.74%Strong Buy
ZBH$93.49$101.21+8.26%Hold
EW$84.37$102.36+21.32%Strong Buy
View Top Medical Device Stocks

Dexcom Stock Forecast FAQ

Is Dexcom Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 17 Wall Street analysts covering (NASDAQ: DXCM) stock is to Strong Buy DXCM stock.

Out of 17 analysts, 13 (76.47%) are recommending DXCM as a Strong Buy, 2 (11.76%) are recommending DXCM as a Buy, 1 (5.88%) are recommending DXCM as a Hold, 0 (0%) are recommending DXCM as a Sell, and 1 (5.88%) are recommending DXCM as a Strong Sell.

If you're new to stock investing, here's how to buy Dexcom stock.

What is DXCM's earnings growth forecast for 2026-2028?

(NASDAQ: DXCM) Dexcom's forecast annual earnings growth rate of 13.34% is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 22.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.83%.

Dexcom's earnings in 2026 is $999,700,000.On average, 32 Wall Street analysts forecast DXCM's earnings for 2026 to be $1,026,534,489, with the lowest DXCM earnings forecast at $928,232,010, and the highest DXCM earnings forecast at $1,089,629,209. On average, 32 Wall Street analysts forecast DXCM's earnings for 2027 to be $1,203,139,327, with the lowest DXCM earnings forecast at $1,061,364,888, and the highest DXCM earnings forecast at $1,303,592,763.

In 2028, DXCM is forecast to generate $1,433,970,907 in earnings, with the lowest earnings forecast at $1,231,101,760 and the highest earnings forecast at $1,624,538,093.

What is DXCM's revenue growth forecast for 2026-2028?

(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 9.71% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.23%.

Dexcom's revenue in 2026 is $4,969,200,000.On average, 32 Wall Street analysts forecast DXCM's revenue for 2026 to be $2,013,219,681,275, with the lowest DXCM revenue forecast at $1,922,275,736,910, and the highest DXCM revenue forecast at $2,083,031,422,800. On average, 32 Wall Street analysts forecast DXCM's revenue for 2027 to be $2,231,334,203,445, with the lowest DXCM revenue forecast at $2,086,805,030,450, and the highest DXCM revenue forecast at $2,353,599,091,305.

In 2028, DXCM is forecast to generate $2,483,411,194,465 in revenue, with the lowest revenue forecast at $2,289,447,761,255 and the highest revenue forecast at $2,661,525,475,545.

What is DXCM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DXCM) forecast ROA is 25.43%, which is higher than the forecast US Medical Devices industry average of 13.68%.

What is DXCM's Price Target?

According to 17 Wall Street analysts that have issued a 1 year DXCM price target, the average DXCM price target is $88.65, with the highest DXCM stock price forecast at $96.00 and the lowest DXCM stock price forecast at $64.00.

On average, Wall Street analysts predict that Dexcom's share price could reach $88.65 by Aug 4, 2027. The average Dexcom stock price prediction forecasts a potential upside of 6.77% from the current DXCM share price of $83.03.

What is DXCM's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DXCM) Dexcom's current Earnings Per Share (EPS) is $2.59. On average, analysts forecast that DXCM's EPS will be $2.72 for 2026, with the lowest EPS forecast at $2.46, and the highest EPS forecast at $2.89. On average, analysts forecast that DXCM's EPS will be $3.19 for 2027, with the lowest EPS forecast at $2.81, and the highest EPS forecast at $3.45. In 2028, DXCM's EPS is forecast to hit $3.80 (min: $3.26, max: $4.31).

What is DXCM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DXCM) forecast ROE is 62.62%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.